We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

339 hedge funds and large institutions have $2.53B invested in Takeda Pharmaceutical in 2019 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 86 increasing their positions, 104 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 38

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

7% more funds holding

Funds holding: 317 → 339 (+22)

3% more capital invested

Capital invested by funds: $2.45B → $2.53B (+$74.7M)

3% more call options, than puts

Call options by funds: $95.2M | Put options by funds: $92.8M

0.81% less ownership

Funds ownership: 9.06% → 8.24% (-0.81%)

17% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 104

Holders
339
Holders Change
+22
Holders Change %
+6.94%
% of All Funds
6.68%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.12%
New
65
Increased
86
Reduced
104
Closed
38
Calls
$95.2M
Puts
$92.8M
Net Calls
+$2.39M
Net Calls Change
+$5.4M

Top Buyers

Rank Fund Capital Flow
1
GCM
Glenview Capital Management
New York
+$60.1M
2
RA
Rovida Advisors
Florida
+$22.1M
3
PPA
Parametric Portfolio Associates
Washington
+$6.53M
4
Millennium Management
Millennium Management
New York
+$6.45M
5
Renaissance Technologies
Renaissance Technologies
New York
+$5.81M

Top Sellers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
-$162M
2
HI
HBK Investments
Texas
-$45.4M
3
Marshall Wace
Marshall Wace
United Kingdom
-$35.7M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$28M
5
LP
LMR Partners
United Kingdom
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$14.5M +$3.08M +161,005 +28%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$14.4M +$1.55M +80,950 +13%
MCPPUI
28
MIC Capital Partners (Public) (US) IM
United Arab Emirates
$14.2M +$13.7M +718,028 New
MC
29
Maverick Capital
Texas
$14.1M -$923K -48,256 -6%
Walleye Trading
30
Walleye Trading
New York
$13.4M +$4.63M +242,099 +55%
PNC Financial Services Group
31
PNC Financial Services Group
Pennsylvania
$11.3M +$37.3K +1,949 +0.3%
Fidelity Investments
32
Fidelity Investments
Massachusetts
$11M -$945K -49,384 -8%
Hudson Bay Capital Management
33
Hudson Bay Capital Management
Connecticut
$10.8M -$11.5M -601,693 -52%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$10.7M -$28M -1,465,417 -73%
VanEck Associates
35
VanEck Associates
New York
$8.74M +$1.34M +70,140 +19%
Tudor Investment Corp
36
Tudor Investment Corp
Connecticut
$8.64M +$27.8K +1,451 +0.3%
OAM
37
Oppenheimer Asset Management
New York
$8.42M -$364K -19,047 -4%
DIA
38
Davidson Investment Advisors
Montana
$8.34M +$89.3K +4,670 +1%
Franklin Resources
39
Franklin Resources
California
$8.33M -$3.12M -163,197 -28%
CCM
40
Cinctive Capital Management
New York
$8.16M +$7.91M +413,400 New
Barclays
41
Barclays
United Kingdom
$8.09M -$461K -24,100 -6%
TAM
42
TFG Asset Management
Cayman Islands
$7.85M – – –
MWNA
43
Marshall Wace North America
New York
$7.32M -$2.71M -141,816 -28%
Voloridge Investment Management
44
Voloridge Investment Management
Florida
$7.25M +$3.51M +183,443 +100%
GF
45
Gabelli Funds
New York
$6.91M +$21K +1,100 +0.3%
SEI Investments
46
SEI Investments
Pennsylvania
$6.81M -$385K -20,118 -5%
Millennium Management
47
Millennium Management
New York
$6.65M +$6.45M +337,271 New
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$6.29M +$96.9K +5,064 +2%
HIMC
49
Heritage Investors Management Corp
Maryland
$6M +$445K +23,249 +8%
VAM
50
Velanne Asset Management
United Kingdom
$5.97M +$2.75K +144 +0%
1
2
3 4 5

TAK Hedge Fund Activity: Q4 2019 in Review

339 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2019, worth a combined $2.53B — up 3% from $2.45B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new TAK positions and 38 closed out — a net gain of 27 holders — while 86 added to existing stakes and 104 trimmed.

The largest buyer was Glenview Capital Management, adding an estimated $60.1M. The largest seller was Baupost Group, exiting entirely with an estimated $162M sold.

  • 339 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2019, up from 317 in Q3 2019.
  • Funds reported $2.53B of Takeda Pharmaceutical stock for Q4 2019, up 3% quarter-over-quarter.
  • 65 funds opened new Takeda Pharmaceutical positions in Q4 2019 and 38 closed out, a net change of +27 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2019 was Glenview Capital Management, an estimated $60.1M added.
  • The largest Takeda Pharmaceutical seller in Q4 2019 was Baupost Group, an estimated $162M sold.

Based on aggregated 13F filings for Q4 2019.